These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 17034300)

  • 21. Efficiency of a New Mesh-Type Nebulizer (NE-SM1 NEPLUS) for Intrapulmonary Delivery of Ipratropium Bromide in Surgical Patients.
    Lee YH; Kwon GY; Park DY; Bang JY; Jang DM; Lee SH; Lee EK; Choi BM; Noh GJ
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):313-9. PubMed ID: 26440415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrostatic charge characteristics of aerosols produced from metered dose inhalers.
    Kwok PC; Glover W; Chan HK
    J Pharm Sci; 2005 Dec; 94(12):2789-99. PubMed ID: 16258995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A correlation equation for the mass median aerodynamic diameter of the aerosol emitted by solution metered dose inhalers.
    Ivey JW; Lewis D; Church T; Finlay WH; Vehring R
    Int J Pharm; 2014 Apr; 465(1-2):18-24. PubMed ID: 24524827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid interrogation of the physical and chemical characteristics of salbutamol sulphate aerosol from a pressurised metered-dose inhaler (pMDI).
    Tong HJ; Fitzgerald C; Gallimore PJ; Kalberer M; Kuimova MK; Seville PC; Ward AD; Pope FD
    Chem Commun (Camb); 2014 Dec; 50(98):15499-502. PubMed ID: 25329335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pulse nebulization in pneumatic devices.
    Gradoń L; Sosnowski TR; Podolec Z
    Int J Occup Saf Ergon; 1999; 5(1):31-42. PubMed ID: 10602637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling and Understanding Combination pMDI Formulations with Both Dissolved and Suspended Drugs.
    Stein SW; Sheth P; Younis US; Mogalian E; Myrdal PB
    Mol Pharm; 2015 Sep; 12(9):3455-67. PubMed ID: 26258647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aerosol characteristics of admixture of budesonide inhalation suspension with a beta2-agonist, procaterol.
    Itazawa T; Adachi Y; Ito Y; Higuchi O; Mochizuki H; Shimojo N; Inoue T
    Allergol Int; 2013 Mar; 62(1):131-5. PubMed ID: 23348859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Output and aerosol properties of 5 nebulizer/compressor systems with arformoterol inhalation solution.
    Bauer A; McGlynn P; Bovet LL; Mims PL; Curry LA; Hanrahan JP
    Respir Care; 2009 Oct; 54(10):1342-7. PubMed ID: 19796414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discriminating Ability of Abbreviated Impactor Measurement Approach (AIM) to Detect Changes in Mass Median Aerodynamic Diameter (MMAD) of an Albuterol/Salbutamol pMDI Aerosol.
    David Christopher J; Patel RB; Mitchell JP; Tougas TP; Goodey AP; Quiroz J; Andersson PU; Lyapustina S
    AAPS PharmSciTech; 2017 Nov; 18(8):3296-3306. PubMed ID: 28589305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The on-line analysis of aerosol-delivered pharmaceuticals via single particle aerosol mass spectrometry.
    Morrical BD; Balaxi M; Fergenson D
    Int J Pharm; 2015 Jul; 489(1-2):11-7. PubMed ID: 25891255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro investigation of drug particulates interactions and aerosol performance of pressurised metered dose inhalers.
    Traini D; Young PM; Rogueda P; Price R
    Pharm Res; 2007 Jan; 24(1):125-35. PubMed ID: 17103336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro deposition properties of nebulized formoterol fumarate: effect of nebulization time, airflow, volume of fill and nebulizer type.
    Okapo SO; Gupta J; Martinez E; Mark R
    Curr Med Res Opin; 2009 Apr; 25(4):807-16. PubMed ID: 19207092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro/in vivo comparisons in pulmonary drug delivery.
    Newman SP; Chan HK
    J Aerosol Med Pulm Drug Deliv; 2008 Mar; 21(1):77-84. PubMed ID: 18518834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro validation of 99mTc-HFA-FP delivered via pMDI-spacer.
    Roller CM; Schaefer NC; Zhang G; Devadason SG
    J Aerosol Med; 2006; 19(3):254-60. PubMed ID: 17034301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adapting the Aerogen Mesh Nebulizer for Dried Aerosol Exposures Using the PreciseInhale Platform.
    Gerde P; Nowenwik M; Sjöberg CO; Selg E
    J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):116-126. PubMed ID: 31613690
    [No Abstract]   [Full Text] [Related]  

  • 36. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Size analysis of a pressurized metered dose inhaler-delivered suspension formulation by the API Aerosizer time-of-flight aerodynamic particle size analyzer.
    Mitchell JP; Nagel MW; Archer AD
    J Aerosol Med; 1999; 12(4):255-64. PubMed ID: 10724640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers.
    Elhissi AM; Karnam KK; Danesh-Azari MR; Gill HS; Taylor KM
    J Pharm Pharmacol; 2006 Jul; 58(7):887-94. PubMed ID: 16805947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is the cellular uptake of respiratory aerosols delivered from different devices equivalent?
    Ong HX; Traini D; Loo CY; Sarkissian L; Lauretani G; Scalia S; Young PM
    Eur J Pharm Biopharm; 2015 Jun; 93():320-7. PubMed ID: 25930239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers.
    Buttini F; Miozzi M; Balducci AG; Royall PG; Brambilla G; Colombo P; Bettini R; Forbes B
    Int J Pharm; 2014 Apr; 465(1-2):42-51. PubMed ID: 24491530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.